Alzheimer’s

Biogen to discontinue development of older Alzheimer’s drug Aduhelm

(Reuters) – Biogen Inc said on Wednesday it would terminate a post-approval study of its first Alzheimer’s drug, Aduhelm, and discontinue all commercialization for the controversial treatment. The strategic shift will help…

Police Search for Missing Alzheimer’s Patient in Toms River

Biogen to discontinue development of older Alzheimer’s drug Aduhelm

Researchers return to Alzheimer’s vaccines, buoyed by recent drug success

Blood tests needed for widespread Alzheimer’s diagnosis on the way

Down syndrome families’ fight for access to Alzheimer’s trials, treatments

Newark Police Seek Assistance in Locating Missing 70-Year-Old Man with Alzheimer’s

Major US health systems expect to offer Alzheimer’s drug Leqembi in a few months

Factbox-Companies in Alzheimer’s race after US nod for Eisai/Biogen drug

Explainer-Who is eligible for the new FDA-approved Alzheimer’s drug?

Medicare offers details on reimbursement for new Alzheimer’s drugs

After weight loss, Alzheimer’s may be next frontier for drugs like Ozempic

Exclusive-Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs

Eisai, Biogen’s Alzheimer’s drug price should not dent demand – analysts

Eisai files for full FDA approval for Alzheimer’s drug Leqembi

Factbox-Who can get the newly approved Eisai and Biogen Alzheimer’s drug?

Roche shutters most trials of Alzheimer’s drug after failed trials

Eisai, Biogen Alzheimer’s drug could be available to some next year

Rare success for Alzheimer’s research unlocks hope for future therapies

73-year-old man with Alzheimers reported missing in Newark

Analysis-Eisai’s trial success raises hope for Alzheimer’s prevention

83-Year-Old Alzheimer’s Patient Reported Missing in Newark

Biogen CEO to leave as Alzheimer’s drug struggles

Alzheimer’s patient groups pressure U.S. to pay for Biogen drug

REPORT: Biogen, Eisai Began Application For Alzheimer’s Drug